Neostigmina Braun (Neostigmine Methylsulfate)

Neostigmine methylsulfate reversibly inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine. This inhibition raises acetylcholine levels at nicotinic receptors in the neuromuscular junction, enhancing muscle contraction, and also stimulates muscarinic receptors in the gut, promoting peristalsis.

The dose of Neostigmina Braun is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and clinical response. Only a qualified healthcare professional should set the dosing regimen.

Safety data for neostigmine methylsulfate in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and under medical supervision.

To request Neostigmina Braun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Neostigmina Braun is an anticholinesterase, whereas alternative reversal agents such as sugammadex act by encapsulating specific neuromuscular blockers. Neostigmine works by increasing acetylcholine levels and may require concomitant anticholinergic therapy to offset muscarinic effects, while sugammadex provides a direct, rapid, and cholinergic‑free reversal for certain agents.

Neostigmina Braun should be stored at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture and direct light, and ensure the container is tightly sealed when not in use.

The product is supplied as a sterile solution for parenteral use and can be given intramuscularly, intravenously, or subcutaneously. Administration technique and rate are determined by the treating physician, taking into account the clinical situation and patient response.

Serious risks include bradycardia, bronchospasm, and cholinergic crisis, which can lead to severe muscle weakness, respiratory compromise, or cardiac arrhythmias. Prompt recognition and appropriate medical intervention are essential if these events occur.

Neostigmina Braun is contraindicated in patients with known hypersensitivity to neostigmine or any excipients, and it should be avoided in individuals with severe bradyarrhythmias, uncontrolled asthma, or other conditions that could be aggravated by excessive cholinergic stimulation.